CRISPR THERAPEUTICS AG · held by 2 funds · data as of 2026-06-03
Sector
Healthcare
Industry
Biotechnology
Market cap
$5.02B
Price
$52.11
12-mo
+24.50%
Held by
2 funds
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an …